We further showed that RENBP inhibition can significantly improve the metabolic labeling efficiency of azido-mannosamine in APCs both in vitro and in vivo. Our study provides a facile approach to improving chemical tagging of APCs for the development of APC-targeted immunotherapies.

We found that murine and human antigen presenting cells (APCs) such as dendritic cells, macrophages, and B cells tend to overexpress RENBP. This could partially explain why azido-mannosamine exhibits low labeling efficiency in APCs.

We show the promise of EV hydrogel for depot cancer vaccine, but can certainly envision diverse applications of this technology in the context of different diseases.

Sorry for that! Please find it here. Thanks for reading. www.nature.com/articles/s41...

Nice work! Congrats!

Thanks Matt for initiating this pack. Can you help add me? Thanks.

Thank you Ute! I guess it is too late, but please help add me if there is still a spot. Thanks!

Can you add me, Monica? Thanks!

Can you add me, Daniel? Thanks!

Thanks Natalie. Can you help add me?

Hi John, can you help add me? Thanks!

Thanks for initiating this pack. Can you help add me? Thanks!

Hi Jon, thanks for initiating the starter pack. Can you help add me to the cancer immunotherapy one? Thanks!